On April 8, 2026, Forte Biosciences, Inc., a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, announced the pricing of a public offering of 5,709,936 shares of its common stock at a price to the public of $26.27 per share. The gross proceeds from the offering are expected to be approximately $150 million before deducting underwriting discounts and commissions and other offering expenses. Wilson Sonsini Goodrich & Rosati advised Forte Biosciences on the transaction.
In addition, Forte has granted the underwriters a 30-day option to purchase up to an additional 856,490 shares of its common stock at the public offering price, less the underwriting discounts and commissions. All the shares of common stock are being offered by Forte. The offering is expected to close on or about April 10, 2026, subject to the satisfaction of customary closing conditions.
The Wilson Sonsini team that advised Forte Biosciences on the transaction was led by Dan Koeppen, David Sharon, Ben Capps, and Brandon Shaw. The team also included:
Corporate
Meg Moloney
Gabriele Forbes-Bennett
Trevor Dorne
Intellectual Property
Mike Hostetler
Minyoung Shin
Employee Benefits and Compensation
Megan Schilling
Alex Manter
Regulatory
Eva Yin
For more information, please see Forte Biosciences’ news release.
